Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia

Neurology

Volumn 67, Issue 12, 2006, Pages 2233-2235

  Jankovic, J ^a   Hunter, C ^a   Dolimbek, B Z ^a   Dolimbek, G S ^a   Adler, C H ^b   Brashear, A ^c   Comella, C L ^d   Gordon, M ^e   Riley, D E ^f   Sethi, K ^g   Singer, C ^h   Stacy, M ⁱ   Tarsy, D ^j   Atassi, M Z ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

^e LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^f UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^g MEDICAL COLLEGE OF GEORGIA   (United States)

^h UNIVERSITY OF MIAMI   (United States)

ⁱ BARROW NEUROLOGICAL INSTITUTE   (United States)

^j BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BLOCKING ANTIBODY; BOTULINUM TOXIN A; BOTULINUM TOXIN B;

ADULT; AGED; ANTIBODY PRODUCTION; ANTIGENICITY; ARTICLE; CERVICAL DYSTONIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DYSTONIA; HUMAN; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MOUSE; MOUSE STRAIN; MULTICENTER STUDY; NONHUMAN; OPEN STUDY; PRIORITY JOURNAL;

BOTULINUM TOXINS; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; TORTICOLLIS; UNITED STATES;

EID: 33845939760     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000249308.66959.43     Document Type: Article

References (10)

1. Jankovic J. Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry 2004;75:951-957.
2. Barnes MP, Best D, Kidd L, et al. The use of botulinum toxin type-B in the treatment of patients who have become unresponsive to botulinum toxin type-A - initial experiences. Eur J Neurol 2005;12:947-955.
3. Factor SA, Molho ES, Evans S, Feustel PJ. Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia. Mov Disord 2005;20:1152-1160.
4. Berman B, Seeberger L, Kumar R. Long-term safety, efficacy, dosing, and development of resistance with botulinum toxin type B in cervical dystonia. Mov Disord 2005;20:233-237.
5. Consky ES, Lang AE. Clinical assessments of patients with cervical dystonia.: Jankovic J, Hallett M, eds. Therapy with botulinum toxin. New York: Marcel Dekker, 1994:211-237.
6. Dressler D, Lange M, Bigalke H. Mouse diaphragm assay for detection of antibodies against botulinum toxin type B. Mov Disord 2005;20:1617-1619.
7. Dolimbek BZ, Jankovic J, Atassi MZ. Cross reaction of tetanus and botulinum neurotoxins A and B and the boosting effect of botulinum neurotoxins A and B on a primary anti-tetanus antibody response. Immunol Invest 2002;31:247-262.
8. Comella CL, Jankovic J, Shannon KM, et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology 2005;65:1423-1429.
9. Tintner R, Gross R, Winzer UF, Smalky KA, Jankovic J. Autonomic function after botulinum toxin type A or B: A double-blind, randomized trial. Neurology 2005;65:765-767.
10. Sankhla C, Jankovic J, Duane D. Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections. Mov Disord 1998;13:150-154.